MetrioPharm AG

 

 

MetrioPharm AG was founded in 2006 in Zurich, Switzerland. The company fully owns and develops all pharmaceutical assets around the compound class MP1000.

The initial goal of MetrioPharm was to scout for and develop active compounds from beyond highly regulated markets (USA, Europe, Japan), that are proven to be efficacious. The company started out with two different families of drugs in the fields of cardiology and inflammatory diseases. Following a complete re-design of one of these early precursor molecules into a stable and well-defined proprietary drug class, named MP1000, the company decided to focus its pipeline fully on this new class of anti-inflammatory and anti-infective agents.

Meanwhile MetrioPharm has successfully completed all pre-clinical work and first-in-man enabling studies for its lead drug MP1032 and is entering the clinical development phase for this drug.